Segantii Capital Management Ltd maintained its position in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Segantii Capital Management Ltd’s holdings in Pfizer were worth $2,053,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the business. Stone House Investment Management LLC increased its holdings in shares of Pfizer by 0.9% during the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the period. Naples Global Advisors LLC increased its holdings in shares of Pfizer by 0.3% during the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares during the period. Pure Financial Advisors Inc. increased its stake in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after acquiring an additional 84 shares during the last quarter. Alpha Windward LLC boosted its position in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 89 shares in the last quarter. Finally, Peachtree Investment Advisors Inc. boosted its position in Pfizer by 1.3% in the first quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 100 shares in the last quarter. 69.00% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/segantii-capital-management-ltd-continues-to-hold-stake-in-pfizer-inc-pfe/1604182.html.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last quarter, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by company insiders.
PFE has been the topic of a number of research analyst reports. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their target price for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Morgan Stanley restated a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. BMO Capital Markets restated a “buy” rating and issued a $37.00 target price on shares of Pfizer in a research report on Wednesday, September 6th. Finally, ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $38.04.
Shares of Pfizer, Inc. (NYSE PFE) opened at 35.96 on Friday. The stock’s 50 day moving average is $33.78 and its 200 day moving average is $33.53. The company has a market capitalization of $213.87 billion, a P/E ratio of 26.31 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.12.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company posted $0.64 EPS. Equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.